Bal Pharma (BOM:524824) Other Stockholders Equity: ₹663 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:524824 Bal Pharma Ltd BOM:524824
65 GF Score
Price ₹85.60
GF Value ₹97.42
Valuation Modestly Undervalued
! 10 Warning Signs
View Full Analysis

What is Bal Pharma Other Stockholders Equity?

Bal Pharma BOM:524824 -0.11% 65 Other Stockholders Equity is ₹663 Mil as of Mar. 2026. GuruFocus rates BOM:524824 with a GF Score™ of 65/100 and a GF Value™ of ₹97.42 (Modestly Undervalued). The stock has 10 warning signs investors should review.

Bal Pharma's Other Stockholders Equity for the quarter that ended in Mar. 2026 was ₹663 Mil.

Bal Pharma's quarterly Other Stockholders Equity declined from Sep. 2025 (₹624 Mil) to Dec. 2025 (₹0 Mil) but then increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹663 Mil).

Bal Pharma's annual Other Stockholders Equity declined from Mar. 2024 (₹29 Mil) to Mar. 2025 (₹22 Mil) but then increased from Mar. 2025 (₹22 Mil) to Mar. 2026 (₹663 Mil).

Bal Pharma Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Bal Pharma's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bal Pharma Other Stockholders Equity Chart

Bal Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 35.47 32.27 28.60 22.07 663.07

Bal Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.07 0.00 624.05 0.00 663.07
BOM:524824
65GF Score
Bal Pharma Ltd BOM:524824
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bal Pharma Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of ₹663 Mil mean?
Bal Pharma (BOM:524824) has a Other Stockholders Equity of ₹663 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Bal Pharma and its competitors.
Is Bal Pharma's Other Stockholders Equity too high?
Bal Pharma's current Other Stockholders Equity is ₹663 Mil. Overall, Bal Pharma has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bal Pharma's Other Stockholders Equity compare to ZTS?
Bal Pharma's Other Stockholders Equity of ₹663 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Bal Pharma and its competitors. Bal Pharma's current Other Stockholders Equity is ₹663 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bal Pharma stock overvalued right now?
Based on GuruFocus' analysis, Bal Pharma (BOM:524824) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹97.42, compared to a current price of ₹85.60 — trading 12.1% below its estimated fair value. The current Other Stockholders Equity is ₹663 Mil. Bal Pharma's overall GF Score™ is 65/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Bal Pharma (BOM:524824), the current Other Stockholders Equity is ₹663 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bal Pharma (BOM:524824) Overvalued in 2026?

Based on GuruFocus' analysis, Bal Pharma stock appears to be undervalued. The current stock price of ₹85.60 is trading 12.1% below its estimated GF Value™ of ₹97.42. GuruFocus considers Bal Pharma to be Modestly Undervalued.

Key valuation signals for BOM:524824:

  • Other Stockholders Equity: ₹663 Mil
  • GF Value™: ₹97.42 vs. price of ₹85.60 (12.1% below fair value)
  • GF Score™: 65/100 with 10 warning signs

No single metric tells the full story. See the BOM:524824 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bal Pharma Business Description

Other Exchanges BALPHARMA:India
Address 10/1, Palace Road, 5th Floor, Lakshmi Narayan Complex, Bengaluru, KA, IND, 560052
Bal Pharma Ltd is a pharmaceutical company. It is principally engaged in the manufacturing and marketing of pharmaceutical formulations and active pharmaceutical ingredients. The company specializes in prescription drugs, generic and over-the-counter products, intravenous infusion, and bulk actives.
65GF Score

Get the complete analysis for BOM:524824

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹85.60
Price
₹97.42
GF Value